Skip to content
Screener

Reported November 12, 2026 · Before market open

EPS-$0.88Miss by $0.16
EPS estimate-$0.72
“We have developed a proposed clinical development plan and look forward to discussing it with the FDA. We remain committed to advancing ARD-101 for patients and families affected by PWS.”
Tien Lee

Next report

Date not yet announced

FAQ

When did Aardvark Therapeutics, Inc. report Q3 2026 earnings?
Aardvark Therapeutics, Inc. (AARD) reported Q3 2026 earnings on November 12, 2026 before market open.
What were Aardvark Therapeutics, Inc.'s Q3 2026 revenue and EPS?
Aardvark Therapeutics, Inc. reported eps of $-0.88 for Q3 2026.
Did Aardvark Therapeutics, Inc. beat estimates in Q3 2026?
EPS missed the consensus estimate of $-0.72 by $0.16.
How did Aardvark Therapeutics, Inc.'s Q3 2026 results compare year-over-year?
Compared to the same quarter a year prior, eps declined 17.3% from $-0.75.
Where can I find Aardvark Therapeutics, Inc.'s Q3 2026 SEC filings?
You can read the 8-K earnings release (0001193125-26-459373) and the 10-Q periodic report (0001193125-26-458957) directly on SEC EDGAR. The filing index links above go to sec.gov.